These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18651225)

  • 1. Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection.
    Sughrue ME; Chang EF; Tyrell JB; Kunwar S; Wilson CB; Blevins LS
    Pituitary; 2009; 12(3):158-64. PubMed ID: 18651225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
    Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
    Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
    Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
    Primeau V; Raftopoulos C; Maiter D
    Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.
    Babey M; Sahli R; Vajtai I; Andres RH; Seiler RW
    Pituitary; 2011 Sep; 14(3):222-30. PubMed ID: 21170594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on prolactinomas. Part 2: Treatment and management strategies.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Giant prolactinomas: clinical management and long-term follow up.
    Shrivastava RK; Arginteanu MS; King WA; Post KD
    J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
    Rohmer V; Freneau E; Morange I; Simonetta C
    Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of dopamine agonist resistance in prolactinoma patients.
    Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
    BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.
    Berinder K; Nyström T; Höybye C; Hall K; Hulting AL
    Pituitary; 2011 Sep; 14(3):199-207. PubMed ID: 21128120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin, prolactin disorders, and dopamine agonists during pregnancy.
    Levin G; Rottenstreich A
    Hormones (Athens); 2019 Jun; 18(2):137-139. PubMed ID: 30341577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine agonist-resistant prolactinomas.
    Oh MC; Aghi MK
    J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
    Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
    J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
    Teixeira M; Souteiro P; Carvalho D
    Pituitary; 2017 Aug; 20(4):464-470. PubMed ID: 28523537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: first results.
    Jaspers C; Benker G; Reinwein D
    Clin Investig; 1994 Jun; 72(6):451-6. PubMed ID: 7950157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.